Roche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases
(RTTNews) - Thursday, Roche (RHHBY) reported new data from the VOYAGER study showing that Vabysmo (faricimab) delivered durable effectiveness and a consistent safety profile in patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edem